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ChemoprophylaxisAbstract Introduction: Patients with rheumatoid arthritis (RA) have increased susceptibility to
infection. The risk of acquiring infection including tuberculosis (TB) in RA may be increased in
patients receiving any immuno-suppressive medication including anti-TNF therapy, which is used
successfully for treating patients with rheumatoid arthritis. The aim of this work was to assess
the risk of TB in RA patients on anti-TNF therapy compared to conventional disease modifying
anti rheumatic drugs when screening for latent TB and TB chemoprophylaxis was applied.
Patients and methods: This study conducted on (235) RA patients indicated for either conven-
tional therapy or anti-TNF therapy from 1-1-2010 to 1-10-2013. Assessment was done before
RA treatment and included medical history, clinical examination, plain chest X-ray, HRCT
chest QuantiFERON-TB Gold in-tube (QFT-GIT) test and microbiologic investigations for
tuberculosis when indicated. All patients with positive QFT-GIT received chemoprophylactic
treatment for TB.
Results: The studied rheumatoid arthritic patients were divided into two groups; group (A)
included (105) RA patients on conventional disease modifying anti rheumatic drugs (DMARDs)
with mean age (51 ± 12) and group (B) included (130) RA patients on anti-TNF therapy with mean
age (48 ± 13). This study showed no signiﬁcant increase of tuberculosis among patients on
anti-TNF therapy (group B) compared to patients on (DMARDs) (group A). Chemo-prophylaxis
in patients on anti-TNF therapy leads to prevention of reactivation of latent TB.
Conclusion: There was no signiﬁcant increased risk for tuberculosis among RA patients receiving
anti-TNF therapy when screening and chemoprophylaxis was applied, so screening of RA patients
before anti-TNF therapy for latent tuberculosis and TB chemoprophylaxis should be done.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Introduction
Patients with rheumatoid arthritis (RA) are reported to have
an increased susceptibility to infection [1]. Studies of a speciﬁc
110 S.R. Samra et al.susceptibility to tuberculosis (TB) in patients with RA have
produced contrasting results. For example in the USA, an
increased incidence of TB in patients with RA was not
observed [2]. In contrast, a substantial increase in the risk of
acquiring TB in RA has been reported in Europe and Asia
[3,4]. The risk of acquiring TB in RA may be increased in
patients receiving oral glucocorticoid therapy or the use of
therapeutic agents that neutralize tumor necrosis factor
(TNF) [5,6].
A new study shows that tuberculosis infection (TB) is
10 times more common among male patients who have rheu-
matoid arthritis than it is in the general population, and that
risk appears to be elevated by treatment with any immunosup-
pressive medication, including anti-TNF therapy, which was
used successfully for treating patients with rheumatoid arthri-
tis. Drugs such as inﬂiximab, adalimumab, and etanercept
have been important treatment advancements because they
allow the direct targeting of the inﬂammatory cytokine tumor
necrosis factor alpha (TNF-a), which is elevated in the blood
and tissue of RA patients [7]. The FDA monitors the safety
of newly licensed products, such as inﬂiximab, adalimumab
and etanercept. Inﬂiximab (Remicade) is a mouse-human
(chimeric) antibody against tumor necrosis factor alpha, intra-
venous infusion of inﬂiximab can be administered in a single
dose (5 mg/kg), a monthly regimen, the loading regimen for
all approved indications occurs at weeks 0, 2, and 6 then every
8 weeks at a clinic or hospital. The half-life of inﬂiximab is
10 days, and its biologic effect persists for up to 2 months. Inf-
liximab is supplied as a sterile, white, lyophilized (freeze dried)
powder 100 mg dose and must be reconstituted [8]. Ada-
limumab, (HUMIRA, Abbott) is a fully human monoclonal
antibody that binds to TNFa, preventing it from activating
TNF receptors. HUMIRA (‘‘Human Monoclonal Antibody
in Rheumatoid Arthritis’’) is marketed in both preloaded
0.8 mL syringes and also in preloaded pen devices (called
Humira Pen), both injected subcutaneously, typically by the
patient at home [9]. Etanercept (Enbrel, Pﬁzer), is a TNF
receptor-IgG fusion protein. A single-use 50 mg auto injector
‘‘pen’’ was used subcutaneously once weekly [10,11]. Evidence
about the beneﬁts of these drugs is accumulating. However,
they are not risk-free, and evidence of their risks primarily
infection especially TB is also mounting so preventive actions
are advised [12].
The aim of this work was to assess the risk of TB associated
with the use of anti-TNF therapy compared to disease modify-
ing anti rheumatic drugs (DMARDs) in RA patients when
screening for latent TB with TB chemoprophylaxis was
applied.
Patients and methods
Study design
A prospective study conducted on (235) rheumatoid arthritic
patients indicated for either conventional therapy or anti-
TNF therapy from 1/1/2010 to 1/10/2013 at the King Fahd
Hospital in Al Madenha Almonoura, Kingdom of Saudi Ara-
bia and Dallah and Nagd hospitals. RA was diagnosed accord-
ing to established classiﬁcation criteria [7] by rheumatologists.
The studied patients were divided into two groups;
group (A) included (105) rheumatoid arthritic patients onconventional disease modifying anti rheumatic drugs
(DMARDs) with mean age (51 ± 12) and group (B) included
(130) rheumatoid arthritic patients on biological therapy with
mean age (48 ± 13) as(55) patients on inﬂiximab, (32) patients
on adalimumab, and (43) patients on etanercept.
Before starting treatment for RA patients they underwent:
(1) Complete medical history.
(2) Clinical examination.
(3) Routine laboratory investigations.
(4) Plain chest X-ray (CXR).
(5) QuantiFERON-TB Gold in-tube (QFT-GIT; Cellestis
Limited, Carnegie, Australia) done according to the
manufacturer instructions.
(6) High resolution computed tomography (HRCT) chest if
chest X-ray (CXR) has any abnormality.
(7) Microbiological investigations to exclude active pul-
monary tuberculosis in clinically suspected cases (AFB
smear, mycobacterial Tuberculosis culture, and real time
polymerase chain reaction).
(8) All patients with positive QFT-GIT received chemopro-
phylactic treatment for TB with INH 5 mg/kg body
weight for 9 months [13] (after excluding active TB by
medical assessment, chest radiography, as well as by
other tests judged appropriate to identify active disease.
Follow up done monthly for:
(1) Any medical complaint especially suggestive of TB
affection.
(2) Clinical examination: general and chest examination.
(3) Radiological and laboratory investigations for TB if the
patient had new symptoms or signs suggestive of TB.
(4) Other investigations as needed e.g. excisional lymph
node biopsy.
A patient was classiﬁed as a TB case when bacteriological
conﬁrmation of TB was done from any specimen obtained
from a patient with an appropriate clinical picture [14].
Patients with active TB received anti TB medication, and
Anti-tumor necrosis factor agents were stopped [15].
Exclusion criteria
Patients with active infection and patients with other immuno-
suppressive diseases were excluded.
Statistical analysis
All statistical analysis was performed using SPSS 12.0 for Win-
dows. Results are expressed as mean and SD. Chi-square test
for qualitative variables were used.
Results
This study was conducted on (235) rheumatoid arthritic
patients. Patients were divided into two groups; group (A)
included (105) RA patients on conventional disease modifying
anti rheumatic drugs with mean age (51 ± 12) and group (B)
included (130) RA patients on biological therapy with mean
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adalimumab, and (43) patients on etanercept.
Table 1 shows characteristics of the studied patient groups,
there was no signiﬁcant difference between two groups
regarding age, sex, smoking, BCG vaccine and positivity of
QFT-GIT.
Table 2 shows infectious complications among two groups,
there was a signiﬁcant increase of respiratory infectious com-
plications among patients on biological therapy (group B) than
patients on DMARDs (group A) as in group (A) the number
of patients who developed respiratory infectious complications
was14 (13.3%) while it was 38 (29.2%) in group (B).
Table 3 Characteristics of patients who developed active
tuberculosis, 4 patients developed TB, one female patient
under DMARDs for RA, with normal chest X-ray and nega-
tive QFT-GIT before starting treatment for RA, 12 months
after starting DMARDs developed pulmonary tuberculosis.
The other three patients were on biological therapy for RA
(2 patients on inﬂiximab and one patient on adalimumab), a
male patient on adalimumab had a normal chest X-ray, previ-
ously was BCG vaccined and had a negative QFT-GIT and
5 months from starting medication developed extra pulmonary
tuberculosis (TB cervical lymphadenitis). 2 male patients on
inﬂiximab had normal chest X-rays, were previously BCG vac-
cinated and moderate smokers and had a negative QFT-GIT
and one patient after 6 months from starting medication devel-
oped extra pulmonary tuberculosis. (TB cervical lymphadeni-
tis).The other patient after 4 weeks from starting medication
developed pulmonary TB.
Discussion
Rheumatoid arthritis (RA) is a chronic, progressive inﬂamma-
tory condition that can lead to a signiﬁcant disability and joint
pain. The cytokine tumor necrosis factor a (TNFa) plays a key
role in its pathogenesis [16]. Introduction of the anti-TNF
therapies has dramatically improved the outcome of severe
RA. While TNFa is a central cytokine in the synovial inﬂam-
mation of RA, it also has an important role in host defense
mechanisms. This may be particularly important with regard
to intracellular infections. Anti-TNF therapies in RA patients,
therefore, have the potential to lead to an increased rate of
infection [17].
From the published reports of clinical trials, there has been
no consistent pattern of serious infection risk associated with
anti-TNF therapy. Some studies show no increased risk in
active treatment groups compared with placebo groups
[18,19], some suggest a possible increased risk [20,21]. The
aim of this work was to assess the risk of TB associated withTable 1 Characteristics of the studied patient groups.
Group A (105)
Age: M± SD (51 ± 12)
Sex No. %
Male 57 54.2
Female 48 45.8
Smoking 76 72.4
BCG vaccine 105 100
+ve QFT-GIT 12 11.4the use of anti-TNF therapy compared to DMARDS in RA
patients when screening for latent TB with TB chemoprophy-
laxis was applied.
This study conducted on (235) patients has RA, is divided
into two groups; group (A) included (105) RA patients on con-
ventional disease modifying anti rheumatic drugs (DMARDs)
with mean age (51 ± 12) and group (B) included (130) RA
patients on anti-TNF therapy with mean age (48 ± 13) as
(55) patients on inﬂiximab, (32) patients on adalimumab,
and (43) patients on etanercept.
Based on previous studies that showed a reduced perfor-
mance of the tuberculin skin test (TST) in immunosuppressed
rheumatoid arthritic subjects [22] and to avoid false positive
TST as all the studied patients were BCG vaccinated, so in this
study QFT-GIT was used instead of TST for screening for
latent TB.
This study showed that among the studied 235 RA patients
25 patients had positive QFT-GIT (10.6%) (Table 1) this ﬁnd-
ing agrees with previous studies [2,3].
In this study there was signiﬁcant increase of respiratory
infectious complications among patients on biological therapy
(group B) than patients on DMARDs (group A), as in group
(A) the number of patients who developed respiratory infec-
tious complications was 14 (13.3%) while it was 38 (29.2%)
in group (B) this ﬁnding agrees with previous ﬁndings of
Andrea Kane (2013) [23].
In the studied patients there was non-signiﬁcant difference
in the number of patients who developed active tuberculosis
between RA patients on DMARDs and patients on anti-
TNF therapies. This ﬁnding does not agree with the study of
Askling et al. (2005) [24] which showed that in RA patients
TNF antagonist treatment was associated with an increased
risk of TB, up to 4-fold in magnitude. This difference in result
may be attributed to the efﬁcacy of chemotherapy in these
study patient groups which decreased the activation of latent
tuberculosis.
In this study the efﬁcacy of screening and anti-TB chemo-
prophylaxis may explain why the time from the beginning of
anti-TNF therapy to TB onset is much higher (5–6 months)
in the present study than in a previous study [25] that found
the median time to develop TB from the beginning of anti-
TNF therapy in patients treated with inﬂiximab was 14 weeks,
when no screening nor TB chemoprophylaxis was done.
Tubach et al. (2009) found an increased risk of TB infection
with early anti-TNF treatment and absence of correct chemo-
prophylactic treatment that favor the reactivation of latent TB
[26]. In the present study, all the patients who developed TB
were new TB cases and no patients with latent TB who
received chemoprophylaxis developed TB reactivation.Group B (130) t/X2 s
(48 ± 13) 1.5 0.07
No. %
70 53.8 0.005 0.9
60 46.2
89 70.8 0.018 0.89
130 100 0.0 1
13 10 0.09 0.76
Table 2 Infectious complications among two groups.
Group A (105) Group B (130) X2 P X2 P
No. % No. %
Upper and lower resp. tract infection 14 13.3 38 29.2 6.09 0.01 3.4 0.3
Urinary tract infection – 0 6 4.6 2.9 0.09
Herpes zoster – 0 4 3.07 1.3 0.23
Active TB 1 .95 3 2.30 0.6 0.42
Table 3 Characteristics of patients who developed active tuberculosis (TB).
No. Age Sex Smoking BCG vaccine QFT-GIT CXR Prophylaxis Treatment TB location TB onset
1 46 F Non Yes ve Normal INH 300 mg/9 m DMARDs Pulmonary 12 m*
2 53 M Mild Yes ve Normal INH 300 mg/9 m Adalimumab Lymph node 5 m*
3 51 M Moderate Yes ve Normal No Inﬂiximab Pulmonary 4 w*
4 39 M Moderate Yes ve Normal INH 300 mg/9 m Inﬂiximab Lymph node 6 m*
* From initiation of therapy to diagnosis of active TB.
112 S.R. Samra et al.Conclusion
This study concluded that TB chemoprophylaxis for RA
patients with latent TB who received anti-TNF therapy is efﬁ-
cient for minimizing reactivation of latent TB, so screening of
these patients before anti-TNF therapy for latent tuberculosis
should be done.
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